News Amgen and Allergan's Avastin biosimilar could face EU delay Amgen and Allergan’s biosimilar of Roche’s cancer blockbuster Avastin has been approved in the EU, but there could be a four-year wait before the drug makes it to the market.
News Allergan and Gedeon Richter set to expand use of bipolar dru... Companies want Vraylar as option bipolar depression
News New Teva CEO axes R&D chief Hayden in boardroom shakeup R&D chief Michael Hayden to leave at year end.
News Judge throws out Allergan patents, criticises Native America... Federal court throws out patents on Restasis
News US lawmaker moves to block Allergan patent deal with tribe Senator Claire McCaskill says deal exploits a “brazen loophole”.
News Teva sells women's health division to tackle $35bn debts Teva has sold its women’s health business in order to pay off some of its $35 billion in debts built up in acquiring Allergan’s generics business.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.